letrozole / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 114 Diseases   361 Trials   361 Trials   7200 News 


«12...6667686970717273747576...100101»
  • ||||||||||  Ibrance (palbociclib) / Pfizer
    Trial completion date, Combination therapy, Metastases:  PALINA: Palbociclib / Letrozole or Fulvestrant in African American Women With HR+ HER2- Breast Cancer (clinicaltrials.gov) -  Dec 18, 2019   
    P2/3,  N=35, Active, not recruiting, 
    Especially with regard to novel endocrine combination therapies, these data imply that some groups of patients will need special attention to guide them through the therapy process. Trial completion date: Dec 2019 --> Jun 2020
  • ||||||||||  Piqray (alpelisib) / Novartis, Kisqali (ribociclib) / Novartis
    Trial primary completion date, Metastases:  CLEE011X2107: Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer (clinicaltrials.gov) -  Dec 17, 2019   
    P1,  N=256, Active, not recruiting, 
    Trial completion date: Dec 2019 --> Jun 2020 Trial primary completion date: Nov 2019 --> Nov 2020
  • ||||||||||  letrozole / Generic mfg., tamoxifen / Generic mfg.
    Trial completion date, Trial primary completion date:  TALES: Fertility Preservation Using Tamoxifen and Letrozole in Estrogen Sensitive Tumors Trial (clinicaltrials.gov) -  Dec 17, 2019   
    P3,  N=144, Recruiting, 
    Trial primary completion date: Nov 2019 --> Nov 2020 Trial completion date: Dec 2019 --> Nov 2020 | Trial primary completion date: Dec 2019 --> Nov 2020
  • ||||||||||  Verzenio (abemaciclib) / Eli Lilly
    Trial completion date, Metastases:  MONARCH plus: A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer (clinicaltrials.gov) -  Dec 17, 2019   
    P3,  N=463, Active, not recruiting, 
    Trial completion date: Dec 2019 --> Nov 2020 | Trial primary completion date: Dec 2019 --> Nov 2020 Trial completion date: Nov 2019 --> Nov 2020
  • ||||||||||  AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma, Irene (pyrotinib) / Jiangsu Hengrui Pharma
    Trial primary completion date, Combination therapy, Metastases:  PLEASURABLE: Pyrotinib, Dalpiciclib(SHR6390) and Endocrine Therapy in Subjects With Dual-receptor Positive(ER+/HER2+) Advanced Breast Cancer (clinicaltrials.gov) -  Dec 10, 2019   
    P1/2,  N=32, Recruiting, 
    Whilst we cannot influence the oestradiol concentration in Letrozole cycles, if the oestradiol is < 400 pmol, patients can be counselled accordingly and may elect not to proceed with IUI, especially if they are paying for treatment themselves. Trial primary completion date: Nov 2019 --> Jun 2020
  • ||||||||||  Ibrance (palbociclib) / Pfizer
    Journal:  Analysis of the selection of CDK4/6 inhibitors based on experience using palbociclib. (Pubmed Central) -  Dec 8, 2019   
    When the number of neutrophils prior to palbociclib introduction was <3,000, neutropenia of grade 3 or higher was observed in all cases following palbociclib introduction. Thus, in order to avoid grade 3 or higher neutropenia and to maintain relative dose intensity, abemaciclib treatment may be considered for cases with neutrophils of <3,000 prior to the introduction of a CDK4/6 inhibitor.
  • ||||||||||  Review, Journal:  Pharmacology of medications used for ovarian stimulation. (Pubmed Central) -  Nov 30, 2019   
    The pharmacology of all current major medications used to stimulate ovarian function is reviewed in this article, including letrozole, clomiphene citrate, gonadotropins, and pulsatile gonadotropin releasing hormone (GnRH). Novel potential compounds and adjuvant treatment approaches are also discussed, such as kisspeptin agonists and androgens.
  • ||||||||||  Ibrance (palbociclib) / Pfizer
    Clinical, Clinical data, Review, Journal, Real-world evidence:  Real-world clinical outcomes and toxicity in metastatic breast cancer patients treated with palbociclib and endocrine therapy. (Pubmed Central) -  Nov 29, 2019   
    Among patients with HR-positive advanced breast cancer, the estimated PFS in patients treated with fulvestrant and palbociclib was comparable to a previously reported phase 3 trial. However, the median PFS with letrozole and palbociclib was shorter than previously reported data from phase 2 and 3 trials. Palbociclib toxicity was very manageable, with a low drug discontinuation rate.
  • ||||||||||  Ibrance (palbociclib) / Pfizer
    Enrollment change, Trial completion date, Trial primary completion date:  Palbociclib and FES PET (clinicaltrials.gov) -  Nov 27, 2019   
    P2,  N=30, Active, not recruiting, 
    L-based therapy is an active therapeutic option and remains a viable option for HER2 + MBC after prior trastuzumab, P and/or T-DM1. N=15 --> 30 | Trial completion date: Nov 2019 --> May 2020 | Trial primary completion date: Nov 2019 --> May 2020
  • ||||||||||  letrozole / Generic mfg., clomifene citrate / Generic mfg.
    New P1 trial:  Pharmacokinetics and Hepatic Safety of EGCG (clinicaltrials.gov) -  Nov 25, 2019   
    P1,  N=36, Not yet recruiting, 
  • ||||||||||  Herceptin (trastuzumab) / Roche
    CARDIAC TOXICITY OF ADJUVANT TRASTUZUMAB IN BREAST CANCER PATIENTS AGED ⩾60 YEARS () -  Nov 23, 2019 - Abstract #AIOM2019AIOM_76;    
    Our results show that, with appropriate pts selection and systematic cardiac assessment, cardiotoxicity in adjuvant trastuzumab therapy is confirmed manageable also in older women. In our experience no serious cardiac events were observed and only 5.3% of pts permanently discontinued treatment because of cardiac toxicity.
  • ||||||||||  Piqray (alpelisib) / Novartis, Kisqali (ribociclib) / Novartis
    Trial primary completion date, Metastases:  CLEE011X2107: Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer (clinicaltrials.gov) -  Nov 20, 2019   
    P1,  N=256, Active, not recruiting, 
    Exemestane is less detrimental to bone health than letrozole in postmenopausal women treated with AI, and this effect may be confined to patients carrying UGT2B17*2, though this finding requires independent validation. Trial primary completion date: Nov 2020 --> Nov 2019
  • ||||||||||  letrozole / Generic mfg.
    New trial:  IUI With Letrozole Versus in Natural Cycle (clinicaltrials.gov) -  Nov 18, 2019   
    P=N/A,  N=966, Not yet recruiting, 
  • ||||||||||  letrozole / generics
    Preclinical, Journal:  Effect of electroacupuncture at different acupoints on follicle development and related factors in serum and ovary tissues of PCOS rats (Pubmed Central) -  Nov 18, 2019   
    EA of CV4, SP6, ST36 and ST36+CV4+SP6 can reduce the number of follicles at the growth stage and regulate the expression levels of gonadotropins in PCOS rats. The effects of EA of CV4 and ST36 are evidently better than those of EA of SP6 in up-regulating serum FSH content and in down-regulating LH/FSH ratio, and serum AMH and INHB levels, and EA of SP6 is evidently superior to EA of CV4 down-regulating LH level, but without synergistic effect among the 3 acupoints.
  • ||||||||||  everolimus / Generic mfg.
    Trial completion date, Trial primary completion date:  Phase II Study of Everolimus Beyond Progression (clinicaltrials.gov) -  Nov 15, 2019   
    P2,  N=3, Active, not recruiting, 
    The effects of EA of CV4 and ST36 are evidently better than those of EA of SP6 in up-regulating serum FSH content and in down-regulating LH/FSH ratio, and serum AMH and INHB levels, and EA of SP6 is evidently superior to EA of CV4 down-regulating LH level, but without synergistic effect among the 3 acupoints. Trial completion date: Oct 2020 --> Nov 2021 | Trial primary completion date: Oct 2019 --> Nov 2020